Steward Partners Investment Advisory LLC Sells 13,779 Shares of Johnson & Johnson (NYSE:JNJ)

Share on StockTwits

Steward Partners Investment Advisory LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 8.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,474 shares of the company’s stock after selling 13,779 shares during the period. Johnson & Johnson makes up 0.8% of Steward Partners Investment Advisory LLC’s investment portfolio, making the stock its 23rd biggest holding. Steward Partners Investment Advisory LLC’s holdings in Johnson & Johnson were worth $22,211,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Zions Bancorporation N.A. lifted its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock valued at $2,810,000 after buying an additional 73 shares during the period. Cambridge Advisors Inc. lifted its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Cambridge Advisors Inc. now owns 22,436 shares of the company’s stock valued at $2,895,000 after buying an additional 78 shares during the period. Vishria Bird Financial Group LLC lifted its stake in shares of Johnson & Johnson by 3.0% in the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after buying an additional 80 shares during the period. Burt Wealth Advisors lifted its stake in shares of Johnson & Johnson by 0.6% in the fourth quarter. Burt Wealth Advisors now owns 12,898 shares of the company’s stock valued at $1,665,000 after buying an additional 82 shares during the period. Finally, Timber Creek Capital Management LLC lifted its stake in shares of Johnson & Johnson by 8.7% in the fourth quarter. Timber Creek Capital Management LLC now owns 1,035 shares of the company’s stock valued at $133,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 67.35% of the company’s stock.

In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.23% of the company’s stock.

NYSE:JNJ opened at $133.42 on Wednesday. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The firm has a market capitalization of $348.48 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 2.23 and a beta of 0.69. The business has a 50-day simple moving average of $134.61.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the prior year, the business posted $2.10 earnings per share. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

Several equities research analysts recently weighed in on JNJ shares. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Thursday, July 18th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 17th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a research note on Thursday, July 18th. Raymond James reduced their target price on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a research note on Wednesday, July 17th. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $148.56.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Special Dividends

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abundance Wealth Counselors Reduces Position in ISHARES TR/CORE MSCI TOTAL INTL STK
Abundance Wealth Counselors Reduces Position in ISHARES TR/CORE MSCI TOTAL INTL STK
Deutsche Bank Initiates Coverage on Encompass Health
Deutsche Bank Initiates Coverage on Encompass Health
Envestnet Inc  Insider William Crager Sells 72,750 Shares
Envestnet Inc Insider William Crager Sells 72,750 Shares
TransDigm Group Incorporated  CEO Sells $5,138,892.00 in Stock
TransDigm Group Incorporated CEO Sells $5,138,892.00 in Stock
Phillips 66  EVP Robert A. Herman Sells 47,433 Shares
Phillips 66 EVP Robert A. Herman Sells 47,433 Shares
Insider Selling: Amazon.com, Inc.  CEO Sells 2,800 Shares of Stock
Insider Selling: Amazon.com, Inc. CEO Sells 2,800 Shares of Stock


© 2006-2019 Ticker Report